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Inflammatory markerAbstract Background: Chronic obstructive pulmonary disease (COPD) is associated with sys-
temic inflammatory consequences. Receptor for advanced glycation end products (RAGE) acts
as an important progression factor amplifying the immune and inflammatory responses in several
pathophysiological conditions. The soluble form of RAGE (sRAGE) acts as a decoy for the recep-
tor ligands and is thus thought to protect against excessive inflammation. Conflicting reports exist
about sRAGE value in stable and exacerbating COPD.
Objective: To assess the sputum to plasma ratio of sRAGE in stable COPD patients.
Subjects and methods: The study included 44 adult patients of both sexes who were presented to
Alexandria Main University Hospital between March and July 2015. Patients were categorized into
three groups; 15 stable COPD patients (Group I), 15 smokers without COPD (Group II), and 14
healthy non-smokers (Group III). Measurement of sRAGE level in induced sputum and plasma
was performed using ELISA technique.
Results: The study included 38 male patients and 6 female patients, whose median ages were 50,
42 and 35.5 years in Groups I, II, and III respectively (p< 0.001). Median FEV1% predicted were
35, 96, and 105% in Groups I, II, and III respectively (p< 0.001). No statistical significant differ-
ence was found among all groups regarding sRAGE level in induced sputum, plasma or sputum/-
plasma ratio (p= 0.092, 0.372, 0.154, respectively). Although levels of sRAGE is apparently higher
in induced sputum rather than in plasma, it lacked significance (r= 0.27, p= 0.08). Furthermore,
no significant correlation was found between either plasma or sputum sRAGE level and predicted
FEV1% (r= 0.11, p= 0.48 and r= 0.12, p= 0.28, respectively).Baess),
574 E.G. Hassanein et al.Conclusions: sRAGE level either in induced sputum, plasma or sputum plasma ratio is not sig-
nificantly different between stable COPD patients, smokers and healthy controls. Thus, sRAGE
cannot be considered as a marker of either diagnosis or severity of COPD.
 2016 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Chronic obstructive pulmonary disease (COPD) is a com-
mon preventable and treatable disease with ongoing sys-
temic inflammation [1,2]. Many of the systemic
manifestations of COPD are mediated through increased
systemic levels of inflammatory proteins such as
interleukin-6, interleukin-8, tumor necrosis factor-a and
C-reactive protein [3].
Receptor for advanced glycation end products (RAGE)
acts as an important progression factor amplifying the immune
and inflammatory responses in several pathophysiological con-
ditions [4].
Soluble RAGE or sRAGE, a secreted isoform, lacks a
transmembrane domain and acts as a decoy for the receptor
ligands and is thus thought to protect against excessive
inflammation [5]. sRAGE represents a naturally occurring
competitive inhibitor of RAGE-mediated signaling pathways
[6]. Conflicting reports exist about sRAGE value in stable
and exacerbating COPD [7]. Thus, our objective was to
assess the sputum to plasma ratio of soluble receptor for
advanced glycation end product (sRAGE) in COPD
patients.
Subjects and methods
The study was carried out on 44 adult patients of both sexes
(38 male patients and 6 female patients), who were presented
to Alexandria Main University Hospital. Patients were
categorized into three groups; 15 stable COPD patients
(Group I), 15 smokers without COPD (Group II), and 14
healthy non-smokers (Group III). All COPD patients and
smoker controls must be current active cigarette smokers.
Patients who have renal or cardiac diseases, diabetes
mellitus, bronchial asthma, granulomatous lung diseases,
malignancy, autoimmune diseases or are receiving
long-term oral corticosteroid therapy were excluded from the
study.
Diagnosis of COPD was made according to Global
Initiative for chronic obstructive lung disease (GOLD) criteria
[1]. Spirometry was done for all patients in the three groups
using clinical spirometer (CHESTGRAPH HI-701; Chest M.
I. Inc., Hongo, Bunkyo-Ku-Tokyo, Japan).
Sputum induction was performed in all patients by receiv-
ing bronchodilator treatment 15 min prior to the procedure,
and then inhaled 3% hypertonic saline solution was delivered
by an ultrasonic nebulizer device (3A Health Care S.r.l.
Lonato del Garda (BS), Italy) for 15 min. Sputum and serum
levels of sRAGE was determined using enzyme-linked
immunosorbent assay (ELISA) (MyBioSource, San Diego,
CA 92195-3308, USA. Catalog #: MBS032029).Samples collection and storage
Five milliliters of blood were withdrawn from each patient on
ethylene-diamine-tetraacetic acid (EDTA) coated vacutainer
tubes. Samples were then centrifuged for 20 min at 3000 rpm
to separate plasma. Plasma was collected in eppendorf tubes
and stored at 20 C till time of assay. Sputum was collected
in sterile containers, the volume of sputum samples was mea-
sured, and the samples were vortexed with phosphate-
buffered solution (PBS). Sputum was then ultracentrifuged at
60,000g for 60 min at 4 C to remove contaminating cellular
debris. This was stored at 20 C for time of assay [8].Assay procedure
On the day of the assay, all reagents were prepared and
brought to room temperature together with the samples
30 min before starting assay procedure. Standard wells, sample
wells and blank (Control) wells were set, 50 ll of standard were
added to each standard well, and 50 ll of sample were added
to each sample well. This was followed by addition of 50 ll
sample diluent to each Blank/Control well. Hundred micro-
liters of HRP-conjugate reagent were added to each well, then
covered with an adhesive strip and incubated for 60 min at
37 C. The microtiter plate was washed 4 times. Fifty micro-
liters of each of chromogen solution A and Chromogen Solu-
tion B were added to each well successively. This was gently
mixed and then protected from light and incubated for
15 min at 37 C. Fifty microliter stop solution was added to
each well. The color in the wells changed from blue to yellow.
The Optical Density (O.D.) was read at 450 nm using a micro-
titer well reader (ELISA Humareader single).
Statistical analysis
Data were fed to the computer and analyzed using IBM SPSS
software package version 20.0. (IBM SPSS Statistics for Win-
dows, Version 20.0., IBM Corp., Armonk, NY) qualitative
data were described using number and percent. Quantitative
data were described using range (minimum and maximum),
mean, standard deviation and median. Comparison between
different groups regarding categorical variables was tested
using Chi-square test. When more than 20% of the cells have
expected count less than 5, correction for chi-square was con-
ducted using Monte Carlo correction. The distributions of
quantitative variables were tested for normality using
Kolmogorov–Smirnov test, Shapiro–Wilk test and D’Agostino
test, if it reveals normal data distribution, parametric tests was
applied. If the data were abnormally distributed, non-
parametric tests were used. For normally distributed
Table 1 Comparison between the three studied groups according to demographic data, anthropometrics and spirometric data.
Group I (COPD) (n= 15) Group II (Smoker) (n= 15) Group III (Healthy) (n= 14) p
Male 13/15 13/15 12/14 1.000
Age (years) 49.13 ± 6.21 42.73a ± 6.26 37.29a,b ± 4.46 <0.001*
Body mass index 24.44 ± 5.07 28.73a ± 5.24 25.16 ± 3.87 0.042*
Weight (kg) 69.87 ± 17.25 85.40 ± 18.44 77.07 ± 15.68 0.057
Height (Cm) 168.40 ± 9.18 170.07 ± 8.94 173.29 ± 10.23 0.379
FEV1% predict 35 (9–78) 96
a (80–121) 105a,b (84–153) <0.001*
FEV1 measure (L) 18 (0.30–2.40) 3.32
a (2.46–4.87) 47a (2.78–7) <0.001*
FEV1/FVC 49.53 ± 14.81 84.73
a ± 6.82 87.50a ± 6.22 <0.001*
FVC% predict 51.47 ± 20.72 89.60a ± 11.72 99.79a ± 17.08 <0.001*
FVC measure (L) 2.08 ± 0.92 4.21a ± 1.01 5.03a ± 1.45 <0.001*
FEF 25–75% predict 18 (9–48) 116a (85–203) 117.5a (91–210) <0.001*
Qualitative data were described using number and percent and was compared using Chi square test, while normally quantitative data were
expressed in mean ± SD and were compared using ANOVA test, abnormally distributed data were expressed in median (Min.–Max.) and were
compared using Kruskal–Wallis test. COPD= chronic obstructive pulmonary disease, FEV1 = Forced expiratory volume in the first second,
FVC= forced vital capacity, FEF = forced expiratory flow.
a Significant with Group I.
b Significant with Group II.
* Statistically significant at p 6 0.05.
Table 2 Comparison between the three studied groups according to Sputum and plasma sRAGE.
Group I (COPD) (n= 15) Group II (Smoker) (n= 15) Group III (Healthy) (n= 14) KW2 p
Plasma sRAGE level (ng/ml) 0.5 (0.3–0.9) 0.4 (0.3–0.7) 0.4 (0.3–0.8) 1.979 0.372
Sputum sRAGE level (ng/ml) 5.4 (2.8–5.45) 5.0 (3.15–5.35) 3.63 (2.53–4.55) 4.778 0.092
Sputum to plasma ratio 6.06 (4.23–15.67) 8.67 (7.0–13.0) 6.28 (4.95–9.91) 3.738 0.154
KW2: Chi square for Kruskal–Wallis test.
Abnormally distributed data were expressed in median (IQR) and were compared using Kruskal–Wallis test. COPD= chronic obstructive
pulmonary disease, sRAGE= soluble receptors for advanced glycation end products.
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analyzed F-test (ANOVA) to be used and Post Hoc test
(LSD). For abnormally distributed data, comparison between
two independent population were done using Mann–Whitney
test while Kruskal–Wallis test was used to compare different
groups and pair wise comparison was assessed using Mann–
Whitney test. Correlations between two quantitative variables
were assessed using Spearman coefficient. Significance of the
obtained results was judged at the 5% level.Results
Between March 2015 and July 2015, 44 subjects/patients were
recruited into this case–control study. Demographic as well as
spirometric data for all recruited subjects were shown in
(Table 1). Notably, there was a statistically significant differ-
ence among the three groups regarding age (p< 0.001), BMI
(p= 0.042), FEV1% predicted, FEV1/FVC, FVC% predicted
and FEF25–75% predicted (p< 0.001).
Levels of plasma sRAGE, sputum sRAGE and sputum to
serum sRAGE ratio were displayed in (Table 2 and Fig. 1).
No statistically significant difference was found among all
groups regarding sRAGE level in induced sputum, plasma or
sputum to plasma ratio (p= 0.092, 0.372, 0.154, respectively).
Although levels of sRAGE is apparently higher in induced
sputum rather than in plasma, it lacked significance
(r= 0.27, p= 0.08).Moreover, there was no significant correlation between
either plasma or sputum sRAGE on one side and measured
or predicted FEV1%, measured or predicted FVC%, and age
or body mass index on the other side (Fig. 2). Notably, there
was a moderate positive correlation between sputum; not
plasma; sRAGE and age (p= 0.047).
Discussion
In the present study, there was a significant difference among
the three groups according to age (p< 0.001) where the
COPD patient group and smoker group were older than the
healthy control group. We found difficulties in recruiting
age-matched older healthy subjects without any medical his-
tory fulfilling the inclusion and exclusion criteria and were
non-smokers. Many papers in the literature were found to
include non-matched age groups in studying RAGE/sRAGE
in COPD patients [9–11].
We did not find a significant association between markers of
airflow limitation and levels of both plasma or sputum sRAGE
(p= 481, p= 275 respectively). While Smith et al. [10] identi-
fied sRAGE as the strongest predictor of FEV1, they postulated
that sRAGE is an even more powerful predictor of COPD than
CRP. In another study by Iwamoto et al. [9] who were the first
to study the relation of sRAGE to progression of airflow
obstruction, they found that decreased sRAGE level in serum
is associated with a longitudinal decline in FEV1/FVC. In other
words, RAGE may protect against COPD progression.
Figure 1 Comparison between the three studied groups as regards plasma sRAGE (ng/ml), sputum sRAGE (ng/ml) or sputum to
plasma sRAGE ratio. Whiskers are minimum and maximum values. Box denotes upper and lower Inter quartile range (IQR) value.
Horizontal lines are the median value. sRAGE= soluble receptors for advanced glycation end products.
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secretions either BAL, sputum or induced sputum; to spiro-
metric parameters in COPD or asthmatic patients is a matter
of debate. The lack of correlation in our study is difficult to
interpret but may be attributed to the small size of recruitedpatients and that 80% of our patients had mild or moderate
obstruction, a fact that necessitates a larger sample size to
establish a relation.
Cross-sectional studies [12–14] in population samples
have shown inverse associations between circulating plasma
Figure 2 Correlation between FEV1% predicted and plasma or sputum sRAGE value in ng/ml. FEV1% predicted = percent predicted
forced expiratory volume in the first second, sRAGE= soluble receptors for advanced glycation end products.
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forms) and anthropometric parameters such as body mass
index (BMI). We similarly found inverse correlation between
BMI and both plasma and sputum sRAGE, but this correla-
tion lacks significance (p= 0.408, p= 0.314, respectively). A
similar result was found in a study by Gopal et al. [11]. It is
widely known that in obesity, the release of interleukins and
other inflammatory cytokines from human adipose tissue is
enhanced [15]. This fact may explain the decreased level of
sRAGE, as an anti-inflammatory marker, in obese patients
with a high BMI.
In our study, plasma sRAGE level showed no significant
difference among the three groups (p= 0.372). Compared to
our results, Miniati et al. [16] who recruited 200 COPD
patients and 201 controls found that plasma sRAGE is signif-
icantly lower in COPD patients than controls. Moreover, Iwa-
moto et al. [9] who recruited 32 nonsmokers, 212 smokers
without COPD and 51 smokers with COPD, found that the
baseline plasma level of sRAGE was lower in smokers with
and without COPD than in nonsmokers. This has also been
reported in many studies [10,11,17].
This can be explained by sRAGE level decrease in acute exac-
erbation like inmost studies but not in stableCOPDpatients like
our study [10,18]. Some studies showed that sRAGE level
increased in acute lung injury [19,20]. This perplexing associa-
tion is further confounded by the effect of comorbidities. As
already shown in previous research, higher sRAGE levels were
found to be protective in rheumatoid arthritis (just like emphy-
sema and COPD) [21], but the opposite was found to be true for
diabetes and cardiovascular disease [22]. Failure to control for
comorbidities may have, thus, been a hurdle to identifying a
specific pattern for sRAGE level in COPD patients.
Moreover, in a recent review Yonchuk et al. [7] show there
is lack of a clinically validated assay and paucity of metaanal-
ysis, as only ‘‘research-grade” assays are currently available for
the measurement of sRAGE. This leads to a wide disparity in
absolute values found between studies reviewed.
To the best of our knowledge, this is the first study to mea-
sure the level of sputum sRAGE in COPD patients.
Regarding the sputum level of sRAGE, our study found no
significant difference among the three groups (p= 0.092). Wefound that level of sRAGE was higher in sputum than in
plasma. This may be explained by the study by Buckley
et al. [23] which found that RAGE was more expressed in
the normal lung than in other tissue under physiological con-
dition and that its soluble isoforms have been shown to be
an important marker of injury to alveolar type I (ATI) cells.
Also in other research based on immunohistochemical studies,
co-localization of RAGE and AGE proteins was noticed in the
pulmonary alveolar macrophages [24,25].
In a study by Uchida et al. [19] they found that RAGE was
released into the alveolar space by injurious and inflammatory
stimuli in the rat lung, and the source was predominantly alve-
olar type I cells. In the injured rat and human lung, RAGE in
the alveolar space and in serum was a soluble isoform sized
approximately 48 kD.
Limitations in the current study may include the small
number of patients recruited and being implemented in a single
rather than multi centers. Despite our best efforts, failure to
select age-matched controls may be added to the limitations.
It would be of more benefit if we included a group of exacer-
bated COPD patients to assess sRAGE before, during and
after exacerbation.
Conclusions
In conclusion, no significant difference was noted between
COPD patients, smokers and healthy controls regarding spu-
tum–plasma ratio of sRAGE. sRAGE levels in sputum is
higher than that of plasma in all studied groups. Further stud-
ies are needed to assess the validity of sRAGE as an inflamma-
tory biomarker in COPD patients.
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